Skin angiosarcoma is a rare and aggressive cancer that begins in the cells lining blood and lymph vessels, most commonly appearing on the scalp, face, or neck. Treatment approaches combine surgery, radiation, and chemotherapy, with researchers actively exploring new therapies—including immunotherapy and targeted drugs—in clinical trials around the world.

Understanding Treatment Goals for Skin Angiosarcoma

When someone receives a diagnosis of skin angiosarcoma, the main goal of treatment is to remove or destroy the cancer, control symptoms, and improve quality of life. Because this cancer grows quickly and tends to spread to other parts of the body, doctors approach treatment aggressively and often use a combination of methods.^[1] The specific treatment plan depends on several factors, including where the tumor is located, how large it has grown, whether it has spread to other areas, and the patient’s overall health.^[10]

Skin angiosarcoma is challenging because it often appears in visible areas like the head and neck, where surgery can be complex and may affect appearance. The disease also has a tendency to come back even after treatment.^[4] For these reasons, medical teams typically include specialists from different fields—surgeons, radiation oncologists, and medical oncologists—who work together to create the best treatment strategy for each person.

There are established treatments that medical societies recommend based on years of research and experience. At the same time, scientists are actively studying new therapies in clinical trials. These trials test innovative drugs and treatment approaches that might offer better outcomes or fewer side effects than current options.^[3] Patients may have the opportunity to participate in these studies, which can provide access to cutting-edge treatments while contributing to medical knowledge.

Standard Treatment Approaches

The cornerstone of treating skin angiosarcoma is surgery. The goal is to remove the entire tumor along with a margin of healthy tissue around it. This margin helps ensure that no cancer cells are left behind.^[10] For angiosarcomas on the scalp or face, surgeons must carefully balance removing enough tissue to eliminate the cancer while preserving function and appearance as much as possible. Sometimes, when the tumor is very large or in a difficult location, complete removal is not possible.^[3]

When angiosarcoma affects the breast—often years after radiation therapy for breast cancer—doctors typically recommend removing the entire breast, a procedure called mastectomy.^[7] This is because breast angiosarcoma tends to grow deep within the tissue and can be difficult to eliminate with less extensive surgery.

Radiation therapy uses high-energy beams like X-rays or protons to kill cancer cells. It plays an important role in treating skin angiosarcoma, either before or after surgery.^[10] When given before surgery, radiation can shrink the tumor, making it easier to remove. When given after surgery, it targets any remaining cancer cells in the area to reduce the chance of the cancer coming back. For patients who cannot have surgery because the tumor is too large or in a location that cannot be safely operated on, radiation therapy may be the primary treatment.^[3]

However, radiation therapy requires special consideration for patients whose angiosarcoma developed after previous radiation treatment for another cancer. In these cases, the area may have already received maximum safe radiation doses, limiting options.^[6]

Chemotherapy involves using drugs to kill cancer cells throughout the body. It becomes particularly important when skin angiosarcoma has spread to other organs, such as the lungs or liver—the most common sites of spread.^[6] Chemotherapy may also be combined with radiation when surgery is not possible.

Among chemotherapy drugs, those in the taxane family—particularly paclitaxel—have shown especially good activity against angiosarcoma. Paclitaxel is often given weekly and has been well tolerated even in patients who have already received other treatments.^[11] Other active chemotherapy regimens include those based on anthracyclines (such as doxorubicin and epirubicin) and gemcitabine-based combinations. Gemcitabine is often paired with other drugs like docetaxel, vinorelbine, or dacarbazine.^[11]

The duration of treatment varies. Surgery is a one-time procedure, though healing takes weeks. Radiation therapy typically continues for several weeks with daily sessions. Chemotherapy may continue for several months, with treatment cycles repeated until the cancer responds or side effects become too severe.^[9]

Side effects depend on the specific treatment. Surgery can cause pain, infection, and scarring, especially for procedures on the head and neck. Radiation therapy may cause skin changes, fatigue, and damage to nearby tissues. Chemotherapy side effects vary by drug but commonly include nausea, fatigue, hair loss, increased infection risk due to lowered blood counts, and nerve damage. The taxane drugs can cause allergic reactions, numbness or tingling in hands and feet, and muscle aches.^[9]

Emerging Therapies in Clinical Trials

Because standard treatments for skin angiosarcoma often fall short—with high recurrence rates and limited effectiveness for advanced disease—researchers are actively testing new approaches in clinical trials. These studies are happening in the United States, Europe, and other regions around the world.

Immunotherapy represents one of the most promising new directions. This approach uses medications called checkpoint inhibitors that help the patient’s own immune system recognize and attack cancer cells. These drugs work by blocking proteins that normally prevent immune cells from attacking the body’s own tissues. When these brakes are released, the immune system can better fight the cancer.^[4]

The checkpoint inhibitors being studied for skin angiosarcoma include drugs targeting proteins called PD-1 and PD-L1. These are the same types of immunotherapy that have shown remarkable success in treating melanoma and other skin cancers.^[4] Scientists believe skin angiosarcoma might respond similarly because it shares certain characteristics with these other cancers, including high levels of genetic mutations, sun damage patterns in the DNA, and the presence of immune cells around tumors.

Several case reports and small studies have documented patients with advanced skin angiosarcoma who responded well to checkpoint inhibitors after other treatments failed.^[12] These trials are typically in Phase I (testing safety), Phase II (testing whether the treatment works), or Phase III (comparing the new treatment to standard therapy). Patients eligible for these trials usually have angiosarcoma that has spread or come back after standard treatment.

Targeted therapy drugs attack specific molecular pathways that cancer cells use to grow. Because angiosarcomas arise from blood vessel cells, they often have abnormalities in genes and proteins that control blood vessel formation. One key protein is called vascular endothelial growth factor, or VEGF, which stimulates new blood vessel growth.^[6]

Several drugs that block VEGF or its receptors have been tested in angiosarcoma patients. Pazopanib is one such drug that blocks multiple proteins involved in blood vessel formation. Studies have shown responses in some patients with advanced angiosarcoma, with reports of tumors shrinking and disease stabilizing for several months.^[11] Researchers have noted particularly good responses in patients whose tumors have specific genetic changes in blood vessel signaling genes.

Another interesting approach being studied involves a common blood pressure medication called propranolol, which belongs to a class of drugs called beta-blockers. Researchers discovered that this inexpensive medication, combined with low doses of chemotherapy drugs like vinblastine and methotrexate given weekly, produced responses in several patients with advanced angiosarcoma.^[11] This approach is called metronomic therapy—using chemotherapy at lower, more frequent doses rather than high doses given less often. Propranolol has even received orphan drug status in Europe for soft tissue sarcoma treatment.

Some clinical trials are exploring whether treating patients with chemotherapy before surgery (called neoadjuvant therapy) can shrink large tumors, making them easier to remove completely. While response rates to preoperative chemotherapy are only about 40 to 50 percent, this approach might help in selected patients with particularly large or difficult-to-reach tumors.^[11]

The mechanism by which these new drugs work varies. Checkpoint inhibitors essentially remove the brakes on the immune system, allowing T-cells to attack cancer. VEGF inhibitors starve tumors by preventing them from forming the new blood vessels they need to grow. Propranolol affects blood vessel cells and may also influence the immune environment around tumors.^[11]

Preliminary results from ongoing trials suggest that some patients experience improvement in disease control, tumor shrinkage, and symptom reduction with these newer approaches. Safety profiles vary—immunotherapy can cause immune-related side effects where the immune system attacks normal organs, while VEGF inhibitors can cause high blood pressure, bleeding, and wound healing problems.^[11]

Most common treatment methods

• Surgery
  • Removal of the tumor along with surrounding healthy tissue to ensure complete cancer elimination
  • Mastectomy (complete breast removal) for breast angiosarcoma following previous radiation therapy
  • Careful surgical planning required for tumors on the scalp, face, and neck to preserve function and appearance
• Radiation Therapy
  • High-energy beams (X-rays or protons) used to kill cancer cells
  • Can be given before surgery to shrink tumors or after surgery to eliminate remaining cancer cells
  • Primary treatment option when surgery is not possible
  • May be limited in patients who previously received radiation for another cancer
• Chemotherapy
  • Paclitaxel (taxane drug) given weekly, showing particular effectiveness in angiosarcoma
  • Anthracycline-based regimens including doxorubicin, epirubicin, and liposomal doxorubicin
  • Gemcitabine-based combinations paired with docetaxel, vinorelbine, or dacarbazine
  • Used when cancer has spread to other organs or combined with radiation when surgery is not an option
• Immunotherapy (Clinical Trials)
  • Checkpoint inhibitors targeting PD-1 or PD-L1 proteins to activate the immune system against cancer
  • Based on promising results in melanoma and other skin cancers with similar immune characteristics
  • Case reports showing responses in patients with advanced disease
• Targeted Therapy (Clinical Trials)
  • Pazopanib blocking VEGF receptors and other proteins involved in blood vessel formation
  • Shows particular promise in patients with genetic alterations in vascular signaling genes
  • Propranolol (beta-blocker) combined with metronomic chemotherapy (low-dose vinblastine and methotrexate)